Literature DB >> 24165155

Comparative pharmacokinetics of factor VIII and recombinant factor IX: for which coagulation factors should half-life change with age?

S Björkman1.   

Abstract

The half-life of factor VIII (FVIII) increases with the age of the patient, while studies on recombinant factor IX (rFIX) and factor VIIa (rFVIIa) have not demonstrated corresponding age-related changes. The purpose of this analysis was to relate the changes in FVIII and rFIX pharmacokinetics (PK) with age to developmental changes in body size and fluid volumes and explain why the elimination half-life of FVIII, but not of rFIX, would change with age, and to consider how the findings could be applied prospectively to other coagulation factors. Published PK data for FVIII from 186 patients aged 1-74 years and for rFIX from 56 patients aged 4-56 years were used. The relationships of FVIII and rFIX clearance (CL) with body weight could be described by allometric expressions. Relative changes in CL with age or weight were similar for FVIII and rFIX. The age-related change in volume of distribution at steady state (V(ss)) of rFIX was parallel to the change in CL in the children while for FVIII the change was much less pronounced. Elimination half-life was clearly age-dependent for FVIII while only a very weak trend could be seen for rFIX. Limited data suggest that rFVIIa in this respect resembles rFIX, with parallel changes in CL and V(ss) producing insignificant change in half-life. To what extent the elimination half-life of a coagulation factor would show a correlation with age can in principle be predicted from the characteristics of its CL and distribution.
© 2013 John Wiley & Sons Ltd.

Entities:  

Keywords:  comparative study; factor IX; factor VIII; half-life; pharmacokinetics

Mesh:

Substances:

Year:  2013        PMID: 24165155     DOI: 10.1111/hae.12253

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  4 in total

Review 1.  Evidence-Based Minireview: For overweight or obese persons with hemophilia A, should factor VIII dosing be based on ideal or actual body weight?

Authors:  Nicoletta Machin; Ming Y Lim
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

Review 2.  The History of Clotting Factor Concentrates Pharmacokinetics.

Authors:  Massimo Morfini
Journal:  J Clin Med       Date:  2017-03-20       Impact factor: 4.241

3.  Fixed doses of N8-GP prophylaxis maintain moderate-to-mild factor VIII levels in the majority of patients with severe hemophilia A.

Authors:  Pratima Chowdary; Manuel Carcao; Pål A Holme; Victor Jiménez-Yuste; Steven R Lentz; Judi Møss; Lone H Poulsen; Chunduo Shen; Alberto Tosetto; Allison Wheeler; Elena Santagostino
Journal:  Res Pract Thromb Haemost       Date:  2019-06-11

4.  A Practical, One-Clinic Visit Protocol for Pharmacokinetic Profile Generation with the ADVATE myPKFiT Dosing Tool in Severe Hemophilia A Subjects.

Authors:  Victor S Blanchette; Laura Zunino; Viviane Grassmann; Chris Barnes; Manuel D Carcao; Julie Curtin; Shannon Jackson; Liane Khoo; Vladimir Komrska; David Lillicrap; Massimo Morfini; Gabriela Romanova; Derek Stephens; Ester Zapotocka; Margaret L Rand; Jan Blatny
Journal:  Thromb Haemost       Date:  2021-04-14       Impact factor: 6.681

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.